Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Exact Sciences's Business Segments
Exact Sciences's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
8
Largest Segment
Screening
Total Revenue
$ 3,247
Regions Reported
3
Revenue Share by Reportable Segment - FY
- Screening78.4%
- Screening Commercial41.8%
- Screening Medicare Parts B C29.1%
- Precision Oncology21.7%
- Screening Other7.5%
- Precision Oncology Medicare Parts B C6%
- Precision Oncology Commercial5.9%
- Precision Oncology Other2.9%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Screening | $ 666 | 78.4% |
| Screening Commercial | $ 355 | 41.8% |
| Screening Medicare Parts B C | $ 247 | 29.1% |
5 more segments available
Sign in to unlock the full Exact Sciences dataset.
Revenue Share by Region - FY
- United States93.2%
- Precision Oncology International6.9%
- Outside of United States6.9%
Revenue by Geographic Region - FY
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| United States | $ 792 | 93.2% |
| Precision Oncology International | $ 59 | 6.9% |
| Outside of United States | $ 59 | 6.9% |
Annual Results
Revenue Share by Region - FY
- Non-US6.9%
Revenue by Geographic Region - FY
| Region | Revenue (Millions) | % of Total |
|---|---|---|
| Non-US | $ 224 | 6.9% |
Description of Exact Sciences
Exact Sciences Corporation is a medical technology company headquartered in Madison, Wisconsin, that is focused on developing and commercializing diagnostic tests for the early detection and prevention of cancer. Founded in 1995, the company has risen to prominence as a leader in the field of molecular diagnostics, a branch of medicine that uses DNA and RNA analysis to identify and diagnose diseases.
The company's flagship product is Cologuard, a non-invasive, at-home fecal immunochemical test (FIT) for colorectal cancer screening. Cologuard uses advanced DNA and protein analysis to detect signs of colorectal cancer and precancerous growths, offering patients a comfortable and convenient alternative to traditional colonoscopies. Since its launch in 2014, Cologuard has become one of the most widely used and highly rated colorectal cancer screening tests in the United States.
In addition to Cologuard, Exact Sciences also offers a suite of other diagnostic products for cancer detection, including Oncotype DX, a genomic test for breast, colon, and prostate cancer; and ThyraMIR, a thyroid cancer test that uses microRNA analysis to detect malignant nodules.
The company has a strong commitment to research and development, with a dedicated team of scientists working to develop new diagnostic tests and improve existing products. In addition to its proprietary diagnostic platforms, Exact Sciences has also formed strategic partnerships with other leading medical technology companies to expand its capabilities in areas such as liquid biopsy and precision medicine.
As of 2021, Exact Sciences has grown to become a multi-billion-dollar company with more than 6,000 employees worldwide. The company has received numerous awards and accolades for its innovative products and commitment to improving healthcare outcomes, and is widely regarded as a leader in the field of molecular diagnostics.
The company's flagship product is Cologuard, a non-invasive, at-home fecal immunochemical test (FIT) for colorectal cancer screening. Cologuard uses advanced DNA and protein analysis to detect signs of colorectal cancer and precancerous growths, offering patients a comfortable and convenient alternative to traditional colonoscopies. Since its launch in 2014, Cologuard has become one of the most widely used and highly rated colorectal cancer screening tests in the United States.
In addition to Cologuard, Exact Sciences also offers a suite of other diagnostic products for cancer detection, including Oncotype DX, a genomic test for breast, colon, and prostate cancer; and ThyraMIR, a thyroid cancer test that uses microRNA analysis to detect malignant nodules.
The company has a strong commitment to research and development, with a dedicated team of scientists working to develop new diagnostic tests and improve existing products. In addition to its proprietary diagnostic platforms, Exact Sciences has also formed strategic partnerships with other leading medical technology companies to expand its capabilities in areas such as liquid biopsy and precision medicine.
As of 2021, Exact Sciences has grown to become a multi-billion-dollar company with more than 6,000 employees worldwide. The company has received numerous awards and accolades for its innovative products and commitment to improving healthcare outcomes, and is widely regarded as a leader in the field of molecular diagnostics.
Exact Sciences Corporation is a molecular diagnostics company dedicated to changing the way cancer is detected and diagnosed, focusing on delivering innovative solutions for cancer screening and diagnostics. The company operates primarily through two main segments: Screening Products and Diagnostic Services, each equipped with unique offerings that serve the healthcare market.
Segments:
1. Screening Products:
Exact Sciences has carved out a niche in the colorectal cancer screening landscape with its non-invasive solutions, designed for patient accessibility and comfort.
- Cologuard: This flagship product represents a significant advancement in colorectal cancer screening. Cologuard is a non-invasive, multi-target stool DNA test that detects certain DNA mutations and the presence of blood in stool samples, indicating potential colorectal cancer or pre-cancerous polyps. It stands out for its ease of use, allowing patients to complete the test in the privacy of their own homes without the need for an invasive procedure, dietary restrictions, or bowel preparation. Clinical studies indicate Cologuard has a high sensitivity rate of 92% for detecting colorectal cancer and 69% for detecting high-risk pre-cancerous polyps. Additionally, it is FDA-approved and widely covered by major health insurance plans, enhancing its accessibility for patients.
Diagnostic Services:
Through its subsidiary, Exact Diagnostics, the company extends its offerings into a broad array of diagnostic testing across various disease states.
- Oncotype DX: This genomic test analyzes the expression of multiple genes within a tumor tissue sample to provide insights into the likelihood of breast cancer recurrence and the effectiveness of chemotherapy. It generates a risk score, enabling oncologists to tailor treatment plans more accurately based on individual tumor biology. Notably, this test has applications beyond breast cancer, including other oncological assessments.
- OncoBlot: This innovative blood test detects specific tumor-associated proteins circulating in the bloodstream. By identifying these biomarkers, OncoBlot can aid in the early detection of diverse cancers, such as lung, prostate, breast, and colorectal cancers. This test is valuable in the clinical setting for both diagnosis and monitoring of disease progression or recurrence.
- COVID-19 Testing: In response to the global pandemic, Exact Sciences has developed molecular diagnostic testing for COVID-19. This test, which is FDA-approved and CLIA-certified, detects the presence of the SARS-CoV-2 virus in respiratory samples, such as nasal swabs and saliva. This offering not only underscores the companys flexibility and responsiveness to emerging health crises but also provides significant value in pandemic management.
Products:
1. Cologuard: As mentioned, this test is pivotal for colorectal cancer screening and enhances early detection. Its non-invasive nature, combined with high sensitivity and accuracy, positions it as a leading choice in this realm.
2. Oncotype DX: This products capability to offer personalized medicine insights through genomic testing is instrumental in shaping treatment decisions, making it a critical tool for oncologists in managing breast cancer and potentially other malignancies.
3. OncoBlot: By serving as a general cancer screening test, OncoBlot opens avenues for early intervention across various cancer types, which can fundamentally alter patient outcomes.
4. COVID-19 Testing: By offering effective and rapid COVID-19 testing solutions, Exact Sciences showcases its agility in addressing urgent public health needs, reinforcing its reputation in the diagnostics sector.
Services:
1. Diagnostic Testing Services: The company’s offerings extend into comprehensive diagnostic testing services, which include genetic, oncology, and infectious disease testing. The testing aims to deliver accurate and timely diagnostic information that helps healthcare professionals in making well-informed decisions regarding patient care options.
2. Patient Support Services: Exact Sciences recognizes the importance of supporting patients throughout their testing process. It provides a robust range of patient support services for individuals using Cologuard, which includes access to live representatives who assist with queries, insurance reimbursement navigation, and educational resources. Additionally, a patient portal enables users to conveniently access their results and effectively manage their screening process online.
Through these extensive and innovative products and services, Exact Sciences Corporation is at the forefront of advancing early cancer detection and diagnosis, driving improvements in patient care, and enhancing outcomes across a range of cancer types. By leveraging cutting-edge technology and a patient-centric approach, the company is positioning itself as a leader in the molecular diagnostics landscape.
Segments:
1. Screening Products:
Exact Sciences has carved out a niche in the colorectal cancer screening landscape with its non-invasive solutions, designed for patient accessibility and comfort.
- Cologuard: This flagship product represents a significant advancement in colorectal cancer screening. Cologuard is a non-invasive, multi-target stool DNA test that detects certain DNA mutations and the presence of blood in stool samples, indicating potential colorectal cancer or pre-cancerous polyps. It stands out for its ease of use, allowing patients to complete the test in the privacy of their own homes without the need for an invasive procedure, dietary restrictions, or bowel preparation. Clinical studies indicate Cologuard has a high sensitivity rate of 92% for detecting colorectal cancer and 69% for detecting high-risk pre-cancerous polyps. Additionally, it is FDA-approved and widely covered by major health insurance plans, enhancing its accessibility for patients.
Diagnostic Services:
Through its subsidiary, Exact Diagnostics, the company extends its offerings into a broad array of diagnostic testing across various disease states.
- Oncotype DX: This genomic test analyzes the expression of multiple genes within a tumor tissue sample to provide insights into the likelihood of breast cancer recurrence and the effectiveness of chemotherapy. It generates a risk score, enabling oncologists to tailor treatment plans more accurately based on individual tumor biology. Notably, this test has applications beyond breast cancer, including other oncological assessments.
- OncoBlot: This innovative blood test detects specific tumor-associated proteins circulating in the bloodstream. By identifying these biomarkers, OncoBlot can aid in the early detection of diverse cancers, such as lung, prostate, breast, and colorectal cancers. This test is valuable in the clinical setting for both diagnosis and monitoring of disease progression or recurrence.
- COVID-19 Testing: In response to the global pandemic, Exact Sciences has developed molecular diagnostic testing for COVID-19. This test, which is FDA-approved and CLIA-certified, detects the presence of the SARS-CoV-2 virus in respiratory samples, such as nasal swabs and saliva. This offering not only underscores the companys flexibility and responsiveness to emerging health crises but also provides significant value in pandemic management.
Products:
1. Cologuard: As mentioned, this test is pivotal for colorectal cancer screening and enhances early detection. Its non-invasive nature, combined with high sensitivity and accuracy, positions it as a leading choice in this realm.
2. Oncotype DX: This products capability to offer personalized medicine insights through genomic testing is instrumental in shaping treatment decisions, making it a critical tool for oncologists in managing breast cancer and potentially other malignancies.
3. OncoBlot: By serving as a general cancer screening test, OncoBlot opens avenues for early intervention across various cancer types, which can fundamentally alter patient outcomes.
4. COVID-19 Testing: By offering effective and rapid COVID-19 testing solutions, Exact Sciences showcases its agility in addressing urgent public health needs, reinforcing its reputation in the diagnostics sector.
Services:
1. Diagnostic Testing Services: The company’s offerings extend into comprehensive diagnostic testing services, which include genetic, oncology, and infectious disease testing. The testing aims to deliver accurate and timely diagnostic information that helps healthcare professionals in making well-informed decisions regarding patient care options.
2. Patient Support Services: Exact Sciences recognizes the importance of supporting patients throughout their testing process. It provides a robust range of patient support services for individuals using Cologuard, which includes access to live representatives who assist with queries, insurance reimbursement navigation, and educational resources. Additionally, a patient portal enables users to conveniently access their results and effectively manage their screening process online.
Through these extensive and innovative products and services, Exact Sciences Corporation is at the forefront of advancing early cancer detection and diagnosis, driving improvements in patient care, and enhancing outcomes across a range of cancer types. By leveraging cutting-edge technology and a patient-centric approach, the company is positioning itself as a leader in the molecular diagnostics landscape.